Expper Competitors

At IBM, we do more than work. We create. We create as technologists, developers, and engineers. We create with our partners. We create with our competitors. If you're searching for ways to make the world work better through technology and infrastructure, software and consulting, then we want to work with you. We're here to help every creator turn their "what if" into what is. Let's create something that will change everything.

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24

Lunit is a leading provider of AI solutions for cancer diagnostics and therapeutics, with a mission to conquer cancer through AI. Our clinically proven AI enables healthcare providers to detect cancer earlier, make more precise treatment decisions, and improve patient outcomes — transforming how cancer is diagnosed and treated. Our technology spans the entire cancer continuum, from risk prediction and screening optimization to early detection and precision oncology. Lunit’s breast and chest imaging AI boosts diagnostic accuracy and efficiency, while our pathology AI is leveraged by leading pharmaceutical companies to drive biomarker discovery and companion diagnostics (CDx) development. Trusted by 10,000+ sites across 65+ countries, Lunit continues to redefine global standards in data-driven cancer care. Learn more about our technology and mission at www.lunit.io/en